Skip to content
Screener

Immunovant, Inc. IMVT Financing Cash Flow

Financing Cash Flow at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
-$8.78B-54.9%
United Community Banks logo
United Community BanksUCB
$73.65M-1.5%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
$325.12M+42,455%
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
$411.17M+66,004%
Summit Therapeutics logo
Summit TherapeuticsSMMT
$3.8M-50.5%
Immunome logo
ImmunomeIMNM
-$135K-100%

Other financials

Income statement

See full
Net income-$147.9M-38.9%
EPS (diluted)-$0.73-15.9%

Balance sheet

See full
Cash & equivalents$902.1M+26.4%
Total debt$72.0K-26.5%
Total equity$852.6M+20.5%
Total assets$957.0M+23.3%

Cash flow

See full
Operating cash flow-$95.1M+14.1%
CapEx$8.0K-96.0%
Free cash flow-$95.1M+14.2%

Valuation

See full
Market cap$8.21B+201%
Enterprise value$7.31B+89.7%

Returns & leverage

See full
Return on equity-64.8%+2.5pp
Debt / equity0.0×
Current ratio9.1×-2.1×

Where this comes from

Reported directly by Immunovant, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The source filing: Immunovant, Inc.’s 10-K, filed May 20, 2026.

Filed
May 20, 2026, 7:28 AM EDT
Fiscal year
FY2026
Accession
0001764013-26-000064
Line itemYears Ended March 31, 2026Years Ended March 31, 2025Years Ended March 31, 2024
Proceeds from issuance of common stock upon underwritten offering, net of underwriter discounts and commissions, and private placement544,194450,000472,745
Payment of offering and private placement costs(504)(319)(6,012)
Proceeds from stock options exercised52,0664,8115,694
Net cash provided by financing activities595,756454,492472,427
Effect of exchange rate changes on cash and cash equivalents(299)747993
Net change in cash and cash equivalents188,13978,606258,833
Cash and cash equivalents – beginning of period713,971635,365376,532
Cash and cash equivalents – end of period$902,110$713,971$635,365

Item 8. Financial Statements and Supplementary Data

FAQ

What is Immunovant, Inc.'s financing cash flow?
Immunovant, Inc. (IMVT) reported financing cash flow of $3.64M in Q1 2026.
How has Immunovant, Inc.'s financing cash flow changed year-over-year?
Immunovant, Inc.'s financing cash flow decreased by 99.2% year-over-year, from $450.61M to $3.64M.
What is the long-term trend for Immunovant, Inc.'s financing cash flow?
Over 3 years (2023 to 2026), Immunovant, Inc.'s financing cash flow has grown at a 103.3% compound annual growth rate (CAGR), from $70.89M to $595.76M.
What does financing cash flow mean?
Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.

Ask your AI about Immunovant, Inc.'s financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude